Treatment with the UroLift™ System does not preclude future UroLift™ System treatments, TURP, or laser procedures.5
About the Procedure
The UroLift™ System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH), including lateral and median lobe hyperplasia, in men 45 years of age or older.
Enlarged Prostate
An enlarged prostate presses on and blocks the urethra, causing bothersome urinary symptoms.
Step 1
The UroLift™ Delivery Device is inserted transurethrally through a rigid sheath under cystoscopic visualization in order to reach the targeted area of obstruction.
Step 2
The obstructing prostatic lobes are retracted by small, permanent UroLift™ Implants which are deployed via a needle that comes out of the delivery device.
Step 3
The UroLift™ System treatment provides fast and reliable symptom relief by opening the obstructed urethra.
Proven Mechanism of Action of the UroLift™ System
|
|
|
|
Patient Selection
The UroLift™ System provides consistent outcomes to a broad range of BPH patients.8
| Prostate Indications for the UroLift™ System✝ | |
|---|---|
| Minimum prostate volume | None |
| Maximum prostate volume | 100 cc |
| Obstructive median lobe | Yes |
The UroLift™ System should not be used if the patient has:
- Prostate volume of >100 cc
- A urinary tract infection
- Urethral conditions that may prevent insertion of a delivery system into the bladder
- Urinary incontinence due to incompetent sphincter
- Current gross hematuria
475,000
BPH patients have been treated with the UroLift™ System9
UroLift™ Delivery Devices and Implants
The full line of UroLift™ products are designed for all prostate types.
"It is our responsibility to educate the patient about all the options. Many of my patients prefer the UroLift™ System procedure over a pill."
